Mirabegron
Obesity Disorder
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 59/ 100
Competitive context
464 Active assets in the Obesity Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
vi-0521 VIVUS LLC | Phase 4 | BBB |
Tirzepatide Royal North Shore Hospital | Phase 4 | BBB |
asc30 Ascletis Pharma (China) Co., Limited | Phase 2 | BBB |
Phentermine Russell McCulloh, MD | Phase 4 | BBB |
Survodutide Boehringer Ingelheim | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Mirabegron is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →